Skip to main content
NCBI home page
American Journal of Alzheimer's Disease and Other Dementias logoLink to American Journal of Alzheimer's Disease and Other Dementias
. 2011 Feb;26(1):10–28. doi: 10.1177/1533317510390351

Review: Risk of Cerebrovascular Adverse Events and Death in Elderly Patients With Dementia When Treated With Antipsychotic Medications: A Literature Review of Evidence

Vikrant Mittal 1, Lekshminarayana Kurup, Deena Williamson 2, Sunanda Muralee 3, Rajesh R Tampi 4
PMCID: PMC10845396  PMID: 21282274

Abstract

Behavioral and Psychological Symptoms of Dementia (BPSD) are increasingly recognized as a major risk factor for caregiver burden, institutionalization, greater impairment in activities of daily living (ADLs), more rapid cognitive decline, and a poorer quality of life. BPSD contribute significantly to the direct and indirect costs of caring for patients with dementia even after adjusting for the severity of cognitive impairment and other co-morbidities. Research on these symptoms has indicated a complex interplay between the biological, psychological and social factors involved in the disease process. Although some psychotropic medications have shown modest efficacy in the treatment of these behaviors, their use has generated controversy due to increasing recognition of the side effects of these medications especially the antipsychotic medications. In this review, we examine the risk of cerebrovascular adverse events (CVAEs) and death with antipsychotic medications when used to treat elderly patients with dementia.

Keywords: dementia, cerebrovascular adverse events, death, antipsychotics

Full Text

The Full Text of this article is available as a PDF (252.3 KB).

Contributor Information

Vikrant Mittal, BJC Healthcare System, Farmington, MO, USA.

Deena Williamson, Masonicare, Wallingford, CT, USA.

Sunanda Muralee, Department of Psychiatry, Yale University School of Medicine, New Haven, CT, USA.

Rajesh R. Tampi, Masonicare, Wallingford, CT, USA, Department of Psychiatry, Yale University School of Medicine, New Haven, CT, USA, rajesh.tampi@yale.edu .

References

  1. Devanand DP, Jacobs DM, Tang MX, et al. The course of psychopathologic features in mild to moderate Alzheimer disease. Arch Gen Psychiatry. 1997. ;54(3):257-263. [DOI] [PubMed] [Google Scholar]
  2. Jeste DV, Finkel SI Psychosis of Alzheimer’s disease and related dementias: diagnostic criteria for a distinct syndrome. Am J Geriatr Psychiatry . 2000;8(1):29-34. [DOI] [PubMed] [Google Scholar]
  3. Paulsen JS, Salmon DP, Thal LJ, et al. Incidence of and risk factors for hallucinations and delusions in patients with probable AD. Neurology. 2000. ;54(10):1965-1971. [DOI] [PubMed] [Google Scholar]
  4. Bharucha AJ, Rosen J., Mulsant BH, Pollock BG Assessment of behavioral and psychological symptoms of dementia. CNS Spectr. 2002;7(11):797-802. [DOI] [PubMed] [Google Scholar]
  5. Lawlor B. Managing behavioural and psychological symptoms of dementia. Br J Psychiatry. 2002;181(6):463-465. [DOI] [PubMed] [Google Scholar]
  6. Alexopoulos GS, Streim J., Carpenter D., Docherty JP Using antipsychotic agents in older patients . J Clin Psychiatry. 2004;65(suppl 2):5-104. [PubMed] [Google Scholar]
  7. Schneider LS , Pollock VE, Lyness SA A metaanalysis of controlled trials of neuroleptic treatment in dementia. J Am Geriatr Soc. 1990. ;38(5):553-563. [DOI] [PubMed] [Google Scholar]
  8. Schneider LS , Tariot PN, Dagerman KS, et al. Effectiveness and safety of atypical antipsychotic drugs in patients with Alzheimers disease . N Engl J Med. 2006;355(15):1525-1538. [DOI] [PubMed] [Google Scholar]
  9. Sultzer DL, Davis SM, Tariot PN, et al. Clinical symptom responses to atypical antipsychotic medications in Alzheimer’s disease: phase 1 outcomes from the CATIE-AD effectiveness trial. Am J Psychiatry. 2008;165(7):844-854. [DOI] [PMC free article] [PubMed] [Google Scholar]
  10. Rosenheck RA , Leslie DL, Sindelar JL, et al. Cost-benefit analysis of second-generation antipsychotics and placebo in a randomized trial of the treatment of psychosis and aggression in Alzheimer disease. Arch Gen Psychiatry. 2007;64(11):1259-1268. [DOI] [PubMed] [Google Scholar]
  11. Siddique H. , Hynan LS, Weiner MF Effect of a serotonin reuptake inhibitor on irritability, apathy, and psychotic symptoms in patients with Alzheimer’s dementia. J Clin Psychiatry. 2009;70(6):915-918. [DOI] [PMC free article] [PubMed] [Google Scholar]
  12. Ling Z., Wendy JM, Dagerman KS, et al. Metabolic changes associated with second-generation antipsychotic use in Alzheimer’s disease patients: the CATIE-AD study. Am J Psychiatry. 2009;166(5):583-590. [DOI] [PMC free article] [PubMed] [Google Scholar]
  13. Gill SS, Bronskill SE, Normand ST, et al. Antipsychotic drug use and mortality in older adults with dementia . Ann Intern Med. 2007;146(11):775-786. [DOI] [PubMed] [Google Scholar]
  14. Sink KM, Holden KF, Yaffe K. Pharmacologic treatment of neuropsychiatric symptoms of dementia: a review of the evidence. JAMA. 2005;293(5):596-608. [DOI] [PubMed] [Google Scholar]
  15. Ballard CG, Waite J., Birks J. Atypical antipsychotics for aggression and psychosis in Alzheimer’s disease (Review). Cochrane Database Syst Rev. 2009;4:1-128. [DOI] [PMC free article] [PubMed] [Google Scholar]
  16. De Deyn PP , Rabheru K., Rasmussen A., et al. A randomized trial of risperidone, placebo and haloperidol for behavioral symptoms of dementia . Neurology. 1999;53(5):946-955. [DOI] [PubMed] [Google Scholar]
  17. Herrmann N. , Lanctot KL Do atypical antipsychotics cause stroke? CNS Drugs. 2005;19(2):91-103. [DOI] [PubMed] [Google Scholar]
  18. http://www.mca.gov.uk/aboutagency/regframework/csm/csmhome.htm . Accessed January 31, 2010. [Google Scholar]
  19. U.S. Food and drug administration. Public health advisory for antipsychotic drugs used for treatment of behavioral disorders in elderly patients. FDA talk paper T05-13. Rockville, MD: : Food and Drug Administration; April 11, 2005. http://www.fda.gov/Drugs/DrugSafety/PublicHealthAdvisories/ucm053171.htm . Accessed September 10, 2009. [Google Scholar]
  20. Brodaty H., Ames D., Snowdon J., et al. A randomized placebo-controlled trial of Risperidone for the treatment of aggression, agitation, and psychosis of dementia. J Clin Psychiatry. 2003; 64(2):134-143. [DOI] [PubMed] [Google Scholar]
  21. De Deyn PP, Katz IR, Brodaty H., Lyons B., Greenspan A., Burns A. Management of agitation, aggression, and psychosis associated with dementia: a pooled analysis including three randomized, placebo-controlled double-blind trials in nursing home residents treated with risperidone. Clin Neurol Neurosurg . 2005;107(6):497-508. [DOI] [PubMed] [Google Scholar]
  22. Schneider LS , Dagerman K., Insel PS Efficacy and adverse effects of atypical antipsychotics for dementia: meta-analysis of randomized, placebo-controlled trials. Am J Geriatr Psychiatry. 2006;14(3):191-210. [DOI] [PubMed] [Google Scholar]
  23. http://www.ema.europa.eu/docs/en_GB/document_library/EPAR_-_Product_Information/human/000471/WC500020170.pdf. Accessed November 23, 2010. [Google Scholar]
  24. Sacchetti E. , Turrina C., Valsecchi P. Cerebrovascular accidents in elderly people treated with antipsychotic drugs: a systemic review. Drug Saf. 2010;33(4):273-288. [DOI] [PubMed] [Google Scholar]
  25. Herrmann N. , Mamdani M., Lanctôt KL Atypical antipsychotics and risk of cerebrovascular accidents. Am J Psychiatry. 2004; 161(6):1113-1115. [DOI] [PubMed] [Google Scholar]
  26. Finkel S., Kozma C., Long S., et al. Risperidone treatment in elderly patients with dementia: relative risk of cerebrovascular events versus other antipsychotics. Int Psychogeriatr. 2005;17(4): 617-629. [DOI] [PubMed] [Google Scholar]
  27. Liperoti R. , Gambassi G., Lapane KL, et al. Cerebrovascular events among elderly nursing home patients treated with conventional or atypical antipsychotics . J Clin Psychiatry. 2005;66(9):1090-1096. [DOI] [PubMed] [Google Scholar]
  28. Formiga F., Fort I., Pe′rez-Castejo′n JM, Ruiz D., Duaso E., Riu S. Association between risperidone treatment and cerebrovascular adverse events in elderly patient with dementia. J Am Geriatr Soc. 2005;53(8):1446-1448. [DOI] [PubMed] [Google Scholar]
  29. Gill SS, Rochon PA, Herrmann N., et al. Atypical antipsychotic drugs and risk of ischemic stroke: population based retrospective cohort study. BMJ. 2005. ;330(7489):445-448. [DOI] [PMC free article] [PubMed] [Google Scholar]
  30. Moretti R., Torre P., Antonello RM, Cattaruzza T., Cazzato G. Olanzapine as a possible treatment of behavioral symptoms in vascular dementia: risks of cerebrovascular events. A controlled, open-label study. J Neurol. 2005;252(10):1186-1193. doi:10.1007/ s00415-005-0830-z. [DOI] [PubMed] [Google Scholar]
  31. Layton D., Harris S., Wilton LV, Shakir SA Comparison of incidence rates of cerebrovascular accidents and transient ischaemic attacks in observational cohort studies of patients prescribed risperidone, quetiapine or olanzapine in general practice in England including patients with dementia. J Psychopharmacol. 2005;19(5):473-482. [DOI] [PubMed] [Google Scholar]
  32. Percudani M. , Barbui C., Fortino I., Tansella M., Petrovich L. Second-generation antipsychotics and risk of cerebrovascular accidents in the elderly. J Clin Psychopharmacol . 2005;25(5): 468-470. [DOI] [PubMed] [Google Scholar]
  33. Kolanowski A., Fick D., Waller JL, Ahern F. Outcomes of antipsychotic drug use in community-dwelling elders with dementia. Arch Psychiatr Nurs. 2006;20(5):217-225. [DOI] [PubMed] [Google Scholar]
  34. Barnett MJ, Wehring H., Perry PJ Comparison of risk of cerebrovasculer events in an elderly VA population with dementia between antipsychotic and nonantipsychotic users. J Clin Psychopharmacol. 2007;27(6):595-601. [DOI] [PubMed] [Google Scholar]
  35. Wang PS, Schneeweiss S., Setoguchi S., et al. Ventricular arrhythmias and cerebrovascular events in the elderly using conventional and atypical antipsychotic medications. J Clin Psychopharmacol. 2007;27(6):707-710. [DOI] [PubMed] [Google Scholar]
  36. Sacchetti E. , Trifiro G., Caputi A., et al. Risk of stroke with typical and atypical anti-psychotics: a retrospective cohort study including unexposed subjects . J Psychopharmacol. 2008. ;22(1):39-46. [DOI] [PubMed] [Google Scholar]
  37. Douglas IJ, Smeeth L. Exposure to antipsychotics and risk of stroke: self controlled case series study. BMJ. 2008;337:a1227. [DOI] [PMC free article] [PubMed] [Google Scholar]
  38. Chan MC, Chong CS, Wu AY, et al. Antipsychotics and risk of cerebrovascular events in treatment of behavioural and psychological symptoms of dementia in Hong Kong: a hospital-based, retrospective, cohort study. Int J Geriatr Psychiatry. 2010;25(4): 362-370. [DOI] [PubMed] [Google Scholar]
  39. Ballard C., Hanney ML, Theodoulou M., et al, DART-AD investigators. The dementia antipsychotic withdrawal trial (DART-AD): long term follow-up of a randomized placebo-controlled trial . Lancet Neurol. 2009;8(2):151-157. [DOI] [PubMed] [Google Scholar]
  40. Schneider LS , Dagerman KS, Insel PS Risk of death with atypical antipsychotic drug treatment for dementia: metaanalysis of randomized placebo-controlled trials. JAMA. 2005;294(15): 1934-1943. [DOI] [PubMed] [Google Scholar]
  41. Nasrallah HA , White T., Nasrallah AT Lower mortality in geriatric patients receiving risperidone and olanzapine versus haloperidol preliminary analysis of retrospective data. Am J Geriatr Psychaitry . 2004;12(4):437-439. [DOI] [PubMed] [Google Scholar]
  42. Raivio MM, Laurila JV, Strandberg TE, Tilvis RS, Pitkala KH Neither atypical nor conventional antipsychotics increase mortality or hospital admissions among elderly patients with dementia: a two-year prospective study . Am J Psychiatry. 2005;162(5):1027. [DOI] [PubMed] [Google Scholar]
  43. Barnett MJ, Perry PJ, Alexander B., Kaboli PJ Risk of mortality associated with antipsychotic and other neuropsychiatric drugs in pneumonia patients. J Clin Psychopharmacol. 2006;26(2): 182-187. [DOI] [PubMed] [Google Scholar]
  44. Suh GH, Shah A. Effect of antipsychotics on mortality in elderly patients with dementia: a 1-year prospective study in a nursing home. Int Psychogeriatr . 2005;17(3):429-441. [DOI] [PubMed] [Google Scholar]
  45. Nonino F., Girolamo GD, Gamberini L., Goldoni CA Survival among elderly Italian patients with dementia treated with atypical antipsychotics: observational study. Neurol Sci. 2006;27(6): 375-380. [DOI] [PubMed] [Google Scholar]
  46. Schneeweiss S. , Setoguchi S., Brookhart A., Dormuth C., Wang PS Risk of death associated with the use of conventional versus atypical antipsychotic drugs among elderly patients. CMAJ. 2007;176(5):627-632. [DOI] [PMC free article] [PubMed] [Google Scholar]
  47. Liperoti R. , Onder G., Landi F., et al. All-cause mortality associated with atypical and conventional antipsychotics among nursin home residents with dementia: a retrospective cohort study. J Clin Psychiatry. 2009;70(10):1340-1347. [DOI] [PMC free article] [PubMed] [Google Scholar]
  48. Rossom RC, Rector TS, Lederle FA, Dysken MW Are all commonly prescribed antipsychotics associated with greater mortality in elderly male veterans with dementia? J Am Geriatr Soc. 2010;58(6):1027-1034. [DOI] [PubMed] [Google Scholar]
  49. Smith DA, Beier MT Association between risperidone treatment and cerebrovascular adverse events: examining the evidence and postulating hypotheses for an underlying mechanism . J Am Med Dir Assoc. 2004;5(2):129-132. [PubMed] [Google Scholar]

Articles from American Journal of Alzheimer's Disease and Other Dementias are provided here courtesy of SAGE Publications

RESOURCES